A detailed history of Marshall Wace, LLP transactions in Mereo Biopharma Group PLC stock. As of the latest transaction made, Marshall Wace, LLP holds 1,028,512 shares of MREO stock, worth $3.92 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,028,512
Previous 1,144,051 10.1%
Holding current value
$3.92 Million
Previous $4.12 Million 2.65%
% of portfolio
0.01%
Previous 0.01%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$3.45 - $4.87 $398,609 - $562,674
-115,539 Reduced 10.1%
1,028,512 $4.23 Million
Q2 2024

Aug 14, 2024

BUY
$2.58 - $4.25 $2.95 Million - $4.86 Million
1,144,051 New
1,144,051 $4.12 Million
Q4 2023

Feb 14, 2024

BUY
$1.19 - $2.42 $17,710 - $36,016
14,883 New
14,883 $34,000
Q1 2022

May 16, 2022

SELL
$1.04 - $1.7 $102,219 - $167,089
-98,288 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$1.51 - $2.59 $80,945 - $138,839
53,606 Added 119.97%
98,288 $157,000
Q2 2021

Aug 13, 2021

SELL
$2.94 - $4.08 $84,895 - $117,814
-28,876 Reduced 39.26%
44,682 $142,000
Q1 2021

May 17, 2021

BUY
$2.6 - $4.43 $191,250 - $325,861
73,558 New
73,558 $248,000

Others Institutions Holding MREO

About Mereo Biopharma Group plc


  • Ticker MREO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 124,986,000
  • Market Cap $476M
  • Description
  • Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...
More about MREO
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.